Summary
We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1.4 mg/m2 (maximum 2.0 mg) on days 1, 8, 15, 22, 29, 36, 43, 50, and 5-fluorouracil 375 mg/m2 on days 15–20, 43–47, 71–75 with leucovorin modulation 500 mg/m2 before each 5FU infusion (MVF). This regimen was utilized as an initial cytoreductive or induction program for these patients prior to high-dose intensification with autologous stem cell rescue. Ten patients (25%) obtained a clinical complete response and six patients (15%) obtained a partial response for an overall response rate of 40%. In addition, 10 patients had evaluable disease that was improved or stable (primarily bone and/or bone marrow metastases) after MVF induction. Thus, 26 patients (65%) were eligible for high-dose intensification with autologous stem cell rescue after MVF induction. Toxicity was primarily a mild mucositis and more commonly peripheral neuropathy. MVF therapy is an active treatment program for metastatic breast cancer but the neurotoxicity makes it difficult to recommend for widespread use.
References
Antman K, Bearman SI, Davidson N, deVries E, Gianni AM, Gisselbrecht C, Kaizer H, Lazarus HM, Livingston RB, Maraninchi E, McElwain IJ, Ogawa M, Peters W, Rosti G, Slease RB, Spitzer G, Tajima T, Vaughan WP, Williams S: High dose therapy in breast cancer with autologous bone marrow support: Current status. In: Gale RP, Champlin RE (eds) New Strategies in Bone Marrow Transplantation. Liss, New York, 1991, p 423
Jones RB, Shpall EJ, Shogan J, Moore J, Gockerman J, Peters WP: AFM induction chemotherapy followed by intensive consolidation with autologous bone marrow support for advanced breast cancer [Abstract 29]. Proc Am Soc Clin Oncol 7: 8, 1988
Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III: A phase II study of high-dose cyclophosphamide, thioTEPA, and carboplatin with autologous marrow support in women with measurable advanced breased cancer responding to standard-dose therapy. J Clin Oncol 10: 102–110, 1992
Dunphy F, Spitzer G, Buzdar A, Hortobagyi GN, Horwitz LJ, Yau J, Spinolo JA, Jaganath S, Holmes F, Wallerstein RO, Bohannan PA, Dicke KA: Treatment of estrogen receptor - negative or hormonally refractory breast cancer with double highdose chemotherapy intensification and bone marrow support. J Clin Oncol 8: 1207–1216, 1990
Peters WP, Shpall EJ, Jones RB, Olsen GA, Bart RC, Grockerman JP, Moore JO: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368–1376, 1988
Williams SF, Gilewski T, Mick R, Bitran JD: High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10: 1743–1747, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williams, S.F., Myers, S.E., Huffman, S. et al. Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. Breast Cancer Res Tr 28, 291–294 (1993). https://doi.org/10.1007/BF00666591
Issue Date:
DOI: https://doi.org/10.1007/BF00666591